iZafe Group
11.11.2021 13:17:31 CET | ACCESS Newswire | Press release
STOCKHOLM, SWEDEN / ACCESSWIRE / November 11, 2021 / iZafe Group (STO:IZAFE-B)
Stockholm, Sweden, iZafe Group AB (publ) ("iZafe" or "the Company") today announced the appointment of Carl-Fredrik Bothén as Chief Marketing Officer. In his new role, Bothén will be an integral part of the executive team as he oversees the development and execution of iZafe marketing initiatives.
Carl-Fredrik has more than 25 years of experience in marketing, communication and digitalization. Among other things, he has worked as Nordic marketing manager for TP-Link Nordic AB and as marketing manager for Sixt rent a car. Carl-Fredrik also has experience from working in growth companies in various stages of development with a focus on, among other things, strategy work and growth. He will also place great emphasis on the Company's IR strategy and in connection with this will also be the contact person for shareholders and investors.
- In our growth journey, it has become natural to create a new position and bring in a senior CMO in the company. With Carl-Fredrik's solid experience in marketing and strategic experience of structured and long-term branding, I am convinced that he will be an important asset in our continued growth journey and management team, says Anders Segerström, CEO of iZafe Group AB.
"With many years of experience working with marketing communication, strategic planning and business development at internationally established companies, I can add expertise to iZafe Group by further developing the business to become a for-profit company. I have at an early stage formed a clear perception of our current situation and see a great potential to together with a very committed organization. I will be able to help increase our brand awareness and demonstrate sales figures, short-term and long-term", says Carl-Fredrik Bothén, CMO at iZafe Group AB.
Contacts
Carl-Fredrik Bothén, Chief Marketing Officer
E-mail: carl-fredrik.bothen@izafegroup.com
Phone number: +46 73-064 48 67
Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12
iZafe Group AB (publ.)
Södra Fiskartorpsvägen 20
114 33 Stockholm
E-mail: ir@izafegroup.com
www.izafe.se/investor-relations/
About Us
iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company's digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.
The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: info@fnca.se . Further information is available at www.izafe.se/investor-relations/ .
Attachments
iZafe Group AB Announces New Chief Marketing Officer Carl-Fredrik Bothén
SOURCE: iZafe Group
View source version on accesswire.com:
https://www.accesswire.com/672329/iZafe-Group-AB-Announces-New-Chief-Marketing-Officer-Carl-Fredrik-Bothn
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
